BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw Y, Chu C. Hepatitis B virus infection. The Lancet 2009;373:582-92. [DOI: 10.1016/s0140-6736(09)60207-5] [Cited by in Crossref: 833] [Cited by in F6Publishing: 349] [Article Influence: 69.4] [Reference Citation Analysis]
Number Citing Articles
1 Hu Z, Liu Y, Zhai X, Dai J, Jin G, Wang L, Zhu L, Yang Y, Liu J, Chu M. New loci associated with chronic hepatitis B virus infection in Han Chinese. Nat Genet. 2013;45:1499-1503. [PMID: 24162738 DOI: 10.1038/ng.2809] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 11.8] [Reference Citation Analysis]
2 Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Xiong J, Zhang H, Wang Y, Wang A, Bian J, Huang H, Zheng Y, Sang X, Xu Y, Lu X, Zhao H. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. Oncotarget 2017;8:107295-302. [PMID: 29291029 DOI: 10.18632/oncotarget.22364] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Wang LC, Chen EQ, Zhu XF, Xiong ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks. Gut Liver. 2011;5:478-485. [PMID: 22195247 DOI: 10.5009/gnl.2011.5.4.478] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Lee J, Park JY, Kim DG, Lee JY, Kim BS, Kim MS, Il Kim S, Kim YS, Huh KH. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 2018;8. [DOI: 10.1038/s41598-018-34111-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
6 Huang YH, Hung HH, Chan CC, Lai CR, Chu CJ, Huo TI, Lee PC, Su CW, Lan KH, Huang HC, Lee IC, Lin HC, Lee SD. Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads. Clin Vaccine Immunol 2010;17:1048-53. [PMID: 20427626 DOI: 10.1128/CVI.00460-09] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hoogeveen RC, Boonstra A. Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. Front Immunol 2020;11:401. [PMID: 32194573 DOI: 10.3389/fimmu.2020.00401] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
8 Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, Yoo BC. A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. J Gut Liver. 2010;4:530-536. [PMID: 21253304 DOI: 10.5009/gnl.2010.4.4.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Seo YS, Kim MN, Kim SU, Kim SG, Um SH, Han KH, Kim YS. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. Medicine (Baltimore). 2016;95:e2985. [PMID: 27015173 DOI: 10.1097/md.0000000000002985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Bian Z, Xiao A, Cao M, Liu M, Liu S, Jiao Y, Yan W, Qi Z, Zheng Z. Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. Virol J 2012;9:275. [PMID: 23158906 DOI: 10.1186/1743-422X-9-275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Liu P, Zhang H, Liang X, Ma H, Luan F, Wang B, Bai F, Gao L, Ma C. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. Oncotarget. 2015;6:29048-29059. [PMID: 26315112 DOI: 10.18632/oncotarget.4804] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
12 Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013;48:13-21. [PMID: 23090000 DOI: 10.1007/s00535-012-0668-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
13 Locarnini SA, Littlejohn M, Yuen LKW. Origins and Evolution of the Primate Hepatitis B Virus. Front Microbiol 2021;12:653684. [PMID: 34108947 DOI: 10.3389/fmicb.2021.653684] [Reference Citation Analysis]
14 Asli M, Kandelouei T, Rahimyan K, Davoodbeglou F, Vaezjalali M. Characterization of Occult Hepatitis B Infection Among Injecting Drug Users in Tehran, Iran. Hepat Mon 2016;16:e34763. [PMID: 27226802 DOI: 10.5812/hepatmon.34763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Taida T, Arai M, Kanda T, Hige S, Ueno Y, Imazeki F, Izumi N, Tanaka E, Shinkai N, Yoshioka K, Nakamoto Y, Nishiguchi S, Tsuge M, Abe M, Sata M, Yatsuhashi H, Ido A, Kita K, Azemoto R, Kitsukawa Y, Goto N, Yokosuka O. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. J Gastroenterol 2017;52:113-22. [PMID: 27306374 DOI: 10.1007/s00535-016-1229-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One. 2014;9:e102051. [PMID: 25025231 DOI: 10.1371/journal.pone.0102051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
17 Chen P, Xie Q, Lu X, Yu C, Xu K, Ruan B, Cao H, Gao H, Li L. Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: A community-based study. Medicine (Baltimore) 2017;96:e7766. [PMID: 28816955 DOI: 10.1097/MD.0000000000007766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjareon W, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tantipanichtheerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study. PLoS One 2017;12:e0173263. [PMID: 28296915 DOI: 10.1371/journal.pone.0173263] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ohno M, Otsuka M, Kishikawa T, Yoshikawa T, Takata A, Koike K. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA. World J Gastroenterol. 2015;21:7084-7088. [PMID: 26109795 DOI: 10.3748/wjg.v21.i23.7084] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chu CM, Lin CC, Lin SM, Lin DY, Liaw YF. Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci. 2012;57:232-238. [PMID: 21837473 DOI: 10.1007/s10620-011-1844-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
21 Deng H, Wang CL, Lai J, Yu SL, Xie DY, Gao ZL. Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients. Hepat Mon 2016;16:e40263. [PMID: 27822268 DOI: 10.5812/hepatmon.40263] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
22 Zhao Y, Zhang XY, Hu Y, Zhang WL, Hu JL, Zeng AZ, Guo JJ, Huang WX, Chen WX, Shan YL, Huang AL. Comparison of a novel real-time PCR assay with sequence analysis, reverse hybridization, and multiplex PCR for hepatitis B virus type B and C genotyping. J Clin Microbiol 2011;49:3392-4. [PMID: 21752975 DOI: 10.1128/JCM.00543-11] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT. Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infect Dis 2018;5:ofx271. [PMID: 29362723 DOI: 10.1093/ofid/ofx271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Hsu YN, Pan CQ, Abbasi A, Xia V, Bansal R, Hu KQ. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans. Dig Dis Sci 2014;59:865-71. [PMID: 24519522 DOI: 10.1007/s10620-014-3054-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
25 Liang KH, Lin CL, Hsu CW, Lai MW, Chien RN, Yeh CT. UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Sci Rep 2016;6:34088. [PMID: 27665939 DOI: 10.1038/srep34088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep 2016;6:33816. [PMID: 27665934 DOI: 10.1038/srep33816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatol 2013;2013:130384. [PMID: 27335823 DOI: 10.1155/2013/130384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, Shaw G, Bell SJ, Desmond PV, Thompson AJ. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol. 2017;9:48-56. [PMID: 28105258 DOI: 10.4254/wjh.v9.i1.48] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
29 Sajid M, Ullah H, Yan K, He M, Feng J, Shereen MA, Hao R, Li Q, Guo D, Chen Y, Zhou L. The Functional and Antiviral Activity of Interferon Alpha-Inducible IFI6 Against Hepatitis B Virus Replication and Gene Expression. Front Immunol 2021;12:634937. [PMID: 33868257 DOI: 10.3389/fimmu.2021.634937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
31 Jung SK, Kim KA, Ha SY, Lee HK, Kim YD, Lee BH, Paik WH, Kim JW, Bae WK, Kim NH. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients. Clin Mol Hepatol. 2015;21:41-48. [PMID: 25834801 DOI: 10.3350/cmh.2015.21.1.41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
32 Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol. 2016;22:1943-1952. [PMID: 26877602 DOI: 10.3748/wjg.v22.i6.1943] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
33 Ma X, Yang Y, Tu H, Gao J, Tan YT, Zheng JL, Bray F, Xiang YB. Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res. 2016;28:150-160. [PMID: 27199512 DOI: 10.21147/j.issn.1000-9604.2016.02.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
34 Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, Lu SN. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. PLoS One 2016;11:e0155544. [PMID: 27177024 DOI: 10.1371/journal.pone.0155544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
35 Gan W, Li J, Zhang C, Chen X, Lin C, Gao Z. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections. BMC Infect Dis 2020;20:931. [PMID: 33287722 DOI: 10.1186/s12879-020-05642-y] [Reference Citation Analysis]
36 Wang L, Zou ZQ, Wang K, Yu JG, Liu XZ. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection. Hepatol Int. 2016;10:133-138. [PMID: 26427997 DOI: 10.1007/s12072-015-9657-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
37 Shimakawa Y, Yan HJ, Tsuchiya N, Bottomley C, Hall AJ. Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: a systematic review. PLoS One. 2013;8:e69430. [PMID: 23894479 DOI: 10.1371/journal.pone.0069430] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
38 Raoult D. Recent and future developments in the epidemiology of the infectious diseases. Eur J Epidemiol 2009;24:393-5. [PMID: 19533385 DOI: 10.1007/s10654-009-9361-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Bing Y, Zhu S, Yu G, Li T, Liu W, Li C, Wang Y, Qi H, Guo T, Yuan Y, He Y, Liu Z, Liu Q. Glucocorticoid-induced S-adenosylmethionine enhances the interferon signaling pathway by restoring STAT1 protein methylation in hepatitis B virus-infected cells. J Biol Chem 2014;289:32639-55. [PMID: 25271158 DOI: 10.1074/jbc.M114.589689] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
40 Dos Anjos GR, Martins RM, Carneiro MA, Brunini SM, Teles SA. Epidemiology of hepatitis B virus infection in first-time blood donors in the southwestern region of Goiás, central Brazil. Rev Bras Hematol Hemoter 2011;33:38-42. [PMID: 23284242 DOI: 10.5581/1516-8484.20110013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Rysgaard CD, Morris CS, Drees D, Bebber T, Davis SR, Kulhavy J, Krasowski MD. Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem. BMC Clin Pathol 2012;12:15. [PMID: 23006828 DOI: 10.1186/1472-6890-12-15] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
42 Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, Zhang X, Zhou J, Mao Q, Ni B. Effects of telbivudine treatment on the circulating CD4+ T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm. 2012;2012:789859. [PMID: 22570512 DOI: 10.1155/2012/789859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
43 Zhao P, Gao Q, He Q, Tan J. Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia. Int J Hematol 2017;106:484-9. [PMID: 28612279 DOI: 10.1007/s12185-017-2276-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
44 Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol 2012;3:351. [PMID: 23420385 DOI: 10.3389/fimmu.2012.00351] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
45 Qin L, Wang F, Zou BW, Ding ZY. Chemotherapy-induced fatal hepatitis B virus reactivation in a small-cell lung cancer patient. Mol Clin Oncol 2016;5:382-4. [PMID: 27699030 DOI: 10.3892/mco.2016.989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
46 Wu Z, Bao H, Yao J, Chen Y, Lu S, Li J, Jiang ZG, Ren JJ, Xu KJ, Ruan B, Yang SG, Xie TS, Hu Y. Suitable hepatitis B vaccine for adult immunization in China: a systematic review and meta-analysis. Hum Vaccin Immunother 2019;15:220-7. [PMID: 30089437 DOI: 10.1080/21645515.2018.1509172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Chen M, Hu P, Ling N, Peng H, Lei Y, Hu H, Zhang D, Ren H. Enhanced functions of peripheral γδ T cells in chronic hepatitis B infection during interferon α treatment in vivo and in vitro. PLoS One 2015;10:e0120086. [PMID: 25774808 DOI: 10.1371/journal.pone.0120086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
48 Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H. Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol. 2013;48:397-404. [PMID: 22850869 DOI: 10.1007/s00535-012-0645-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
49 Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827-834. [PMID: 20688564 DOI: 10.1016/s1470-2045(10)70167-4] [Cited by in Crossref: 129] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
50 Chiang CH, Huang KC. Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:7213-7216. [PMID: 24966591 DOI: 10.3748/wjg.v20.i23.7213] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
51 Al-Azzam S, Ding Y, Liu J, Pandya P, Ting JP, Afshar S. Peptides to combat viral infectious diseases. Peptides 2020;134:170402. [PMID: 32889022 DOI: 10.1016/j.peptides.2020.170402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
52 Li Y, Yin S, Chen Y, Zhang Q, Huang R, Jia B, Jie W, Yao K, Wang J, Tong X, Liu Y, Wu C. Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4. J Cell Mol Med 2020;24:6096-106. [PMID: 32391647 DOI: 10.1111/jcmm.15202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020;26:883-903. [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
54 Li H, Sheng C, Liu H, Liu G, Du X, Du J, Zhan L, Li P, Yang C, Qi L, Wang J, Yang X, Jia L, Xie J, Wang L, Hao R, Xu D, Tong Y, Zhou Y, Zhou J, Sun Y, Li Q, Qiu S, Song H. An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation. Int J Biol Sci 2016;12:1104-13. [PMID: 27570484 DOI: 10.7150/ijbs.16064] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
55 Ramos-Lopez O, Martinez-Lopez E, Roman S, Fierro NA, Panduro A. Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World J Gastroenterol. 2015;21:11552-11566. [PMID: 26556986 DOI: 10.3748/wjg.v21.i41.11552] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
56 Wei W, Wu Q, Zhou J, Kong Y, You H. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. Int J Environ Res Public Health 2015;12:10039-55. [PMID: 26308024 DOI: 10.3390/ijerph120810039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
57 Wang L, Wu XP, Zhang W, Zhu DH, Wang Y, Li YP, Tian Y, Li RC, Li Z, Zhu X. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS One. 2011;6:e17608. [PMID: 21408128 DOI: 10.1371/journal.pone.0017608] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
58 Yang SG, Wang B, Chen P, Yu CB, Deng M, Yao J, Zhu CX, Ren JJ, Wu W, Ju B, Shen JF, Chen Y, Li MD, Ruan B, Li L. Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation. PLoS One 2012;7:e47808. [PMID: 23094094 DOI: 10.1371/journal.pone.0047808] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
59 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635-7643. [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 10.8] [Reference Citation Analysis]
60 Chang PY, Huang CC, Hung CH, Yu CY, Wu DK, Hwang JI, Liang PC, Wu RH, Tsai WL, Lin YJ, Liu YS, Liang HL, Lee RC, Chen CH. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer 2018;7:312-22. [PMID: 30488021 DOI: 10.1159/000487608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Huang R, Wang G, Tian C, Liu Y, Jia B, Wang J, Yang Y, Li Y, Sun Z, Yan X. Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China. Sci Rep. 2017;7:8543. [PMID: 28819319 DOI: 10.1038/s41598-017-09234-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
62 Tooyama M, Tamori A, Nakano A, Hai H, Thuy le TT, Enomoto M, Kawada N. A pregnant woman with acute hepatitis B in whom vertical transmission was prevented by tenofovir disoproxil fumarate. Clin J Gastroenterol 2013;6:173-6. [PMID: 26181458 DOI: 10.1007/s12328-013-0370-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, Urbani S, Chong YS, Guccione E, Bertoletti A. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun. 2015;6:6588. [PMID: 25807344 DOI: 10.1038/ncomms7588] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 14.7] [Reference Citation Analysis]
64 Bertani S, Pineau P, Loli S, Moura J, Zimic M, Deharo E, Ruiz E. An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations. PLoS One 2013;8:e67756. [PMID: 23840771 DOI: 10.1371/journal.pone.0067756] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
65 Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, Dai L. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord. 2014;15:449. [PMID: 25532827 DOI: 10.1186/1471-2474-15-449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
66 Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infect Dis 2017;17:9. [PMID: 28056849 DOI: 10.1186/s12879-016-2121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Chiesa A, Ochola E, Oreni L, Vassalini P, Rizzardini G, Galli M. Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? PLoS One 2020;15:e0242278. [PMID: 33206693 DOI: 10.1371/journal.pone.0242278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Kitab B, Alj HS, Ezzikouri S, Benjelloun S. MicroRNAs as Important Players in Host-hepatitis B Virus Interactions. J Clin Transl Hepatol 2015;3:149-61. [PMID: 26357642 DOI: 10.14218/JCTH.2015.00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
69 Assis DR, Tenore Sde B, Pinho JR, Lewi DS, Ferreira PR. Characteristics of an outpatient chronic hepatitis B virus infection cohort. Einstein (Sao Paulo) 2015;13:189-95. [PMID: 26154539 DOI: 10.1590/S1679-45082015AO3269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
70 Heiberg IL, Pallett LJ, Winther TN, Høgh B, Maini MK, Peppa D. Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clin Exp Immunol 2015;179:466-76. [PMID: 25311087 DOI: 10.1111/cei.12470] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
71 Kramvis A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol 2016;26:285-303. [PMID: 27139263 DOI: 10.1002/rmv.1885] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
72 Liu Y, Wen J, Chen J, Xu C, Hu Y, Zhou YH. Rare detection of occult hepatitis B virus infection in children of mothers with positive hepatitis B surface antigen. PLoS One 2014;9:e112803. [PMID: 25383543 DOI: 10.1371/journal.pone.0112803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
73 Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4:691-699. [PMID: 21286339 DOI: 10.1007/s12072-010-9213-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
74 Song A, Wang X, Lu J, Jin Y, Ma L, Hu Z, Zheng Y, Shen C, Chen X. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis. J Viral Hepat 2021;28:601-12. [PMID: 33455067 DOI: 10.1111/jvh.13471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Dana D, Zary N, Peyman A, Behrooz A. Risk prison and hepatitis B virus infection among inmates with history of drug injection in Isfahan, Iran. ScientificWorldJournal 2013;2013:735761. [PMID: 23737725 DOI: 10.1155/2013/735761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
76 Jie Y, Li X, Lin G, Wu Y, Li X, Gao Z, Chong Y. Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation study. Hepatol Int 2014;8:501-7. [PMID: 26202755 DOI: 10.1007/s12072-014-9551-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
78 Liang JH, Gao R, Dai JC, Gale RP, Li W, Fan L, Hu ZB, Xu W, Li JY. The prognostic role of HBV infection in chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2018;144:1309-15. [PMID: 29761374 DOI: 10.1007/s00432-018-2663-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
79 Lee S, Park JY, Song K, Kim DY, Kim BK, Kim SU, Ku HJ, Han KH, Ahn SH. Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. Gut Liver 2015;9:776-83. [PMID: 25963085 DOI: 10.5009/gnl14297] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
80 Ko WS, Shen FP, Shih CJ, Chiou YL. The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase. Nutrients 2020;12:E321. [PMID: 31991892 DOI: 10.3390/nu12020321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Zhang H, Li C, Kwok ST, Zhang QW, Chan SW. A Review of the Pharmacological Effects of the Dried Root of Polygonum cuspidatum (Hu Zhang) and Its Constituents. Evid Based Complement Alternat Med 2013;2013:208349. [PMID: 24194779 DOI: 10.1155/2013/208349] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
82 Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014;20:401-413. [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
83 Matos MA, Ferreira RC, Rodrigues FP, Marinho TA, Lopes CL, Novais AC, Motta-Castro AR, Teles SA, Souto FJ, Martins RM. Occult hepatitis B virus infection among injecting drug users in the Central-West Region of Brazil. Mem Inst Oswaldo Cruz 2013;108:S0074-02762013000300386. [PMID: 23778654 DOI: 10.1590/S0074-02762013000300019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
84 Ma J, Zhang Y, Chen X, Jin Y, Chen D, Wu Y, Cui J, Wang H, Liu J, Li N, Gao F. Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One 2013;8:e67606. [PMID: 23935839 DOI: 10.1371/journal.pone.0067606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Lee WC, Lee CS, Wang YC, Cheng CH, Wu TH, Lee CF, Soong RS, Chang ML, Wu TJ, Chou HS, Chan KM. Validation of the Model for End-Stage Liver Disease Score Criteria in Urgent Liver Transplantation for Acute Flare Up of Hepatitis B. Medicine (Baltimore) 2016;95:e3609. [PMID: 27258492 DOI: 10.1097/MD.0000000000003609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
86 Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, Sarikaya D, Atay MH, Yucel I. The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours. J Int Med Res 2016;44:627-38. [PMID: 27048386 DOI: 10.1177/0300060516638992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
87 Lee IC, Huang YH, Su CW, Wang YJ, Huo TI, Lee KC, Lin HC. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. PLoS One. 2013;8:e76798. [PMID: 24124595 DOI: 10.1371/journal.pone.0076798] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
88 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
89 Chen WC, Cheng JS, Chiang PH, Tsay FW, Chan HH, Chang HW, Yu HC, Tsai WL, Lai KH, Hsu PI. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy. PLoS One. 2015;10:e0131545. [PMID: 26121480 DOI: 10.1371/journal.pone.0131545] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
90 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
91 Sang X, Wang R, Han Y, Zhang C, Shen H, Yang Z, Xiong Y, Liu H, Liu S, Li R, Yang R, Wang J, Wang X, Bai Z, Xiao X. T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model. Acta Pharm Sin B 2017;7:311-8. [PMID: 28540167 DOI: 10.1016/j.apsb.2017.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
92 Tang S, Yue M, Wang J, Su J, Yu R, Zhou D, Xu K, Cai L, Zhang Y, Wang J. Association of genetic variants in estrogen receptor α with HCV infection susceptibility and viral clearance in a high-risk Chinese population. Eur J Clin Microbiol Infect Dis 2014;33:999-1010. [PMID: 24395301 DOI: 10.1007/s10096-013-2038-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
93 Miao B, Lao XM, Lin GL. Post-transplant withdrawal of lamivudine results in fatal hepatitis flares in kidney transplant recipients, under immune suppression, with inactive hepatitis B infection. Afr Health Sci. 2016;16:1094-1100. [PMID: 28479903 DOI: 10.4314/ahs.v16i4.27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Xie DY, Wang SM, Yang JM, Wang LH, Chen HY, Huai C, Shang J, Mao Q, Lei CL, Luo GH, Qian J, Lu DR. IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection. World J Gastroenterol 2016;22:9813-21. [PMID: 27956805 DOI: 10.3748/wjg.v22.i44.9813] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
95 Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis. World J Gastroenterol. 2012;18:6290-6301. [PMID: 23180951 DOI: 10.3748/wjg.v18.i43.6290] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
96 Fan YC, Zhang YY, Sun YY, Wang N, Xiao XY, Wang K. Altered expression of A20 gene in peripheral blood mononuclear cells is associated with the progression of chronic hepatitis B virus infection. Oncotarget 2016;7:68821-32. [PMID: 27634895 DOI: 10.18632/oncotarget.11993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
97 Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol. 2014;20:9486-9496. [PMID: 25071343 DOI: 10.3748/wjg.v20.i28.9486] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
98 Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, Wang XM, Wang W, Lv DX, Li J, Deng YQ, Wang Y, Huo N, Yu M, Xi HL, Liu D, Zhou YX, Wang GQ, Xia NS, Zhang MX. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) 2014;93:e322. [PMID: 25546679 DOI: 10.1097/MD.0000000000000322] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
99 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. J Clin Med 2021;10:353. [PMID: 33477752 DOI: 10.3390/jcm10020353] [Reference Citation Analysis]
100 Sekiba K, Otsuka M, Ohno M, Kishikawa T, Yamagami M, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels. Oncotarget 2018;9:20953-64. [PMID: 29765512 DOI: 10.18632/oncotarget.25104] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
101 Chen J, Xu W, Chen Y, Xie X, Zhang Y, Ma C, Yang Q, Han Y, Zhu C, Xiong Y, Wu K, Liu F, Liu Y, Wu J. Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling. J Virol 2017;91:e01824-16. [PMID: 28122987 DOI: 10.1128/JVI.01824-16] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
102 Zu J, Zhuang G, Liang P, Cui F, Wang F, Zheng H, Liang X. Estimating age-related incidence of HBsAg seroclearance in chronic hepatitis B virus infections of China by using a dynamic compartmental model. Sci Rep 2017;7:2912. [PMID: 28588249 DOI: 10.1038/s41598-017-03080-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
103 Yang S, Yu C, Chen P, Deng M, Cao Q, Li Y, Ren J, Xu K, Yao J, Xie T, Wang C, Cui Y, Ding C, Tian G, Wang B, Zhang X, Ruan B, Li L. Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China. Sci Rep 2015;5:18334. [PMID: 26655735 DOI: 10.1038/srep18334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
104 Yu X, Zhang D, Shi B, Ren G, Peng X, Fang Z, Kozlowski M, Zhou X, Zhang X, Wu M, Wang C, Yuan Z. Oral administered particulate yeast-derived glucan promotes hepatitis B virus clearance in a hydrodynamic injection mouse model. PLoS One 2015;10:e0123559. [PMID: 25856080 DOI: 10.1371/journal.pone.0123559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
105 Coppola N, Corvino AR, De Pascalis S, Signoriello G, Di Fiore E, Nienhaus A, Sagnelli E, Lamberti M. The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. BMC Infect Dis. 2015;15:149. [PMID: 25884719 DOI: 10.1186/s12879-015-0874-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
106 Du M, Zhang S, Xiao L, Xu Y, Liu P, Tang Y, Wei S, Xing M, Miao X, Yao P. The Relationship between Serum Bilirubin and Elevated Fibrotic Indices among HBV Carriers: A Cross-Sectional Study of a Chinese Population. Int J Mol Sci 2016;17:E2057. [PMID: 27941693 DOI: 10.3390/ijms17122057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
107 Wang Y, Xiong J, Niu M, Chen X, Gao L, Wu Q, Zheng K, Xu K. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget 2017;8:59666-76. [PMID: 28938670 DOI: 10.18632/oncotarget.19611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
108 Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One 2013;8:e78672. [PMID: 24205292 DOI: 10.1371/journal.pone.0078672] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
109 Wu ZQ, Tan L, Liu T, Gao ZL, Ke WM. Evaluation of changes of serum hepatitis B surface antigen from a different perspective. World J Gastroenterol 2015;21:2739-45. [PMID: 25759544 DOI: 10.3748/wjg.v21.i9.2739] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Mun E, Lee W, Nam MW, Kim HI, Kim H, Lee Y, Park S. Cross-sectional association between long working hours and liver function: the Kangbuk Samsung Health Study. BMJ Open 2020;10:e041595. [PMID: 33376174 DOI: 10.1136/bmjopen-2020-041595] [Reference Citation Analysis]
111 Seremba E, Van Geertruyden JP, Ssenyonga R, Opio CK, Kaducu JM, Sempa JB, Colebunders R, Ocama P. Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda. Vaccine 2017;35:2937-42. [PMID: 28434689 DOI: 10.1016/j.vaccine.2017.04.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
112 Shyu HJ, Lung CC, Ho CC, Sun YH, Ko PC, Huang JY, Pan CC, Chiang YC, Chen SC, Liaw YP. Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: an ecological study. BMC Public Health 2013;13:352. [PMID: 23590585 DOI: 10.1186/1471-2458-13-352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
113 Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol 2017;17:154. [PMID: 29221441 DOI: 10.1186/s12876-017-0697-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
114 Zhou J, Song L, Zhao H, Yan L, Ma A, Xie S, Zhang X, Zhang D, Xie Q, Zhang G, Shang J, Cheng J, Zhao W, Zou Z, Zhang M, Xia N, Wang G. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. Sci Rep 2017;7:2747. [PMID: 28584279 DOI: 10.1038/s41598-017-03102-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
115 Zhang J, Zhang Y, Wang Q, Li C, Deng H, Si C, Xiong H. Interleukin-35 in immune-related diseases: protection or destruction. Immunology 2019;157:13-20. [PMID: 30681737 DOI: 10.1111/imm.13044] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
116 Ko YL, Sun CS, Chung KM, Lin YM, Feng IC, Sheu MJ, Koay LB, Lin CY, Ho CH, Kuo HT. Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. PLoS One. 2015;10:e0117590. [PMID: 25689069 DOI: 10.1371/journal.pone. 0117590] [Reference Citation Analysis]
117 Zhan MR, Gao XZ, Wang C, Peng F, Wang XM, Xu HQ, Niu JQ. Elevated soluble 4-1BB is associated with serum markers of hepatitis B virus in patients with chronic hepatitis B. World J Clin Cases 2021;9:1619-30. [PMID: 33728305 DOI: 10.12998/wjcc.v9.i7.1619] [Reference Citation Analysis]
118 Zhao Y, Zhang XY, Guo JJ, Zeng AZ, Hu JL, Huang WX, Shan YL, Huang AL. Simultaneous genotyping and quantification of hepatitis B virus for genotypes B and C by real-time PCR assay. J Clin Microbiol 2010;48:3690-7. [PMID: 20720032 DOI: 10.1128/JCM.00741-10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021;9:5769-81. [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
120 Rijckborst V, Janssen HL. The Role of Interferon in Hepatitis B Therapy. Curr Hepat Rep 2010;9:231-8. [PMID: 20949114 DOI: 10.1007/s11901-010-0055-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
121 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 645] [Article Influence: 77.2] [Reference Citation Analysis]
122 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-165] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
123 Valizadeh L, Zamanzadeh V, Negarandeh R, Zamani F, Hamidia A, Zabihi A. Psychological Reactions among Patients with Chronic Hepatitis B: a Qualitative Study. J Caring Sci 2016;5:57-66. [PMID: 26989666 DOI: 10.15171/jcs.2016.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
124 Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One 2019;14:e0222221. [PMID: 31584951 DOI: 10.1371/journal.pone.0222221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
125 Nie H, Evans AA, London WT, Block TM, Ren XD. Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach. J Clin Microbiol 2011;49:2440-8. [PMID: 21562108 DOI: 10.1128/JCM.02472-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
126 Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget 2017;8:92431-41. [PMID: 29190928 DOI: 10.18632/oncotarget.21369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
127 Song C, Lv J, Liu Y, Chen JG, Ge Z, Zhu J, Dai J, Du LB, Yu C, Guo Y, Bian Z, Yang L, Chen Y, Chen Z, Liu J, Jiang J, Zhu L, Zhai X, Jiang Y, Ma H, Jin G, Shen H, Li L, Hu Z; China Kadoorie Biobank Collaborative Group. Associations Between Hepatitis B Virus Infection and Risk of All Cancer Types. JAMA Netw Open 2019;2:e195718. [PMID: 31199446 DOI: 10.1001/jamanetworkopen.2019.5718] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 16.5] [Reference Citation Analysis]
128 Alavian SM, Imanieh MH, Imanieh MH. Predictive Factors in the Incidence of Cirrhosis in Chronic Hepatitis B Virus Infections. Hepat Mon. 2016;16:e34790. [PMID: 27330536 DOI: 10.5812/hepatmon.34790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
129 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014;20:12045-55. [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Yan YP, Su HX, Ji ZH, Shao ZJ, Pu ZS. Epidemiology of Hepatitis B Virus Infection in China: Current Status and Challenges. J Clin Transl Hepatol. 2014;2:15-22. [PMID: 26356070 DOI: 10.14218/jcth.2013.00030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
131 Su TH, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen CL, Chen PJ, Kao JH, Chen DS. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One. 2013;8:e55916. [PMID: 23437072 DOI: 10.1371/journal.pone.0055916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
132 Zhuo Y, Yang Y, Zhang M, Xu Y, Chen Z, Mu L, Tang X, Zhong Z, Chen J, Zhou L. Single Nucleotide Polymorphisms in IFN-γ Signaling Pathway Associated with Risk of Hepatitis B Virus Infection in Chinese Children. Can J Infect Dis Med Microbiol 2020;2020:8121659. [PMID: 32047575 DOI: 10.1155/2020/8121659] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Nam H, Nilles KM, Levitsky J, Ison MG. Donor-derived Viral Infections in Liver Transplantation. Transplantation 2018;102:1824-36. [PMID: 29979345 DOI: 10.1097/TP.0000000000002326] [Cited by in Crossref: 10] [Article Influence: 5.0] [Reference Citation Analysis]
134 Liu C, Wang YM, Fan K. Epidemiological and clinical features of hepatitis B virus related liver failure in China. World J Gastroenterol. 2011;17:3054-3059. [PMID: 21799653 DOI: 10.3748/wjg.v17.i25.3054] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
135 Park MS, Kim SW, Yoon KT, Kim SU, Park SY, Tak WY, Kweon YO, Cho M, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. Gut Liver. 2016;10:275-282. [PMID: 26087790 DOI: 10.5009/gnl14391] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
136 Chen P, Yu C, Wu W, Wang J, Ruan B, Ren J, Yang S, Xu K, Yu L, Li L. Serolological Profile Among HBsAg-Positive Infections in Southeast China: A Community-Based Study. Hepat Mon 2013;13:e7604. [PMID: 23483608 DOI: 10.5812/hepatmon.7604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
137 Zhang J, Zong L, Wang Y, Li C, Chen C, Wen Y, Li J, Tong S. Core gene insertion in hepatitis B virus genotype G functions at both the encoded amino acid sequence and RNA structure levels to stimulate core protein expression. Virology 2019;526:203-13. [PMID: 30415131 DOI: 10.1016/j.virol.2018.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Roman S, Jose-Abrego A, Fierro NA, Escobedo-Melendez G, Ojeda-Granados C, Martinez-Lopez E, Panduro A. Hepatitis B virus infection in Latin America: a genomic medicine approach. World J Gastroenterol. 2014;20:7181-7196. [PMID: 24966588 DOI: 10.3748/wjg.v20.i23.7181] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
139 Wang Y, Xiong J, Chen X, Niu M, Chen X, Guan Y, Zheng K, Xu K. Hepatitis B virus infection and decreased risk of stroke: a meta-analysis. Oncotarget 2017;8:59658-65. [PMID: 28938669 DOI: 10.18632/oncotarget.19609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
140 Chu CM, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer 2012;107:2010-5. [PMID: 23079574 DOI: 10.1038/bjc.2012.474] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
141 Madihi S, Syed H, Lazar F, Zyad A, Benani A. A Systematic Review of the Current Hepatitis B Viral Infection and Hepatocellular Carcinoma Situation in Mediterranean Countries. Biomed Res Int 2020;2020:7027169. [PMID: 32626758 DOI: 10.1155/2020/7027169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
142 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol. 2011;17:2945-2952. [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
143 Wang Y, Wang F, Zhao H, Zhang X, Chen H, Zhang K. Human adipose-derived mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vitro. Int J Mol Sci 2014;15:6096-110. [PMID: 24727377 DOI: 10.3390/ijms15046096] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
144 Song Y, Shen Y, Xia X, Zhang AM. Association between genetic polymorphisms of the IL28B gene and leukomonocyte in Chinese hepatitis B virus-infected individuals. PeerJ 2017;5:e4149. [PMID: 29302390 DOI: 10.7717/peerj.4149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
145 Tag-Adeen M, Omar MZ, Abd-Elsalam FM, Hasaneen A, Mohamed MA, Elfeky HM, Said EM, Abdul-Aziz B, Osman AH, Ahmed ES, Osman GS, Abdul-Samie T. Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes. Medicine (Baltimore) 2018;97:e9781. [PMID: 29419671 DOI: 10.1097/MD.0000000000009781] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
146 Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2010;2:348-359. [PMID: 21160806 DOI: 10.4251/wjgo.v2.i9.348] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
147 Chen M, Hu P, Peng H, Zeng W, Shi X, Lei Y, Hu H, Zhang D, Ren H. Enhanced peripheral γδT cells cytotoxicity potential in patients with HBV-associated acute-on-chronic liver failure might contribute to the disease progression. J Clin Immunol 2012;32:877-85. [PMID: 22415432 DOI: 10.1007/s10875-012-9678-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
148 Taechangam N, Kol A, Arzi B, Borjesson DL. Multipotent Stromal Cells and Viral Interaction: Current Implications for Therapy. Stem Cell Rev Rep 2021. [PMID: 34347271 DOI: 10.1007/s12015-021-10224-9] [Reference Citation Analysis]
149 Almeida RW, Mello FCDA, Menegoy IV, Santo MPDE, Ginuíno CF, Sousa PSF, Villar LM, Lampe E, Lewis-Ximenez LL. Detection and molecular characterisation of a diagnosis escape variant associated with occult hepatitis B virus in Brazil. Mem Inst Oswaldo Cruz 2017;112:485-91. [PMID: 28591309 DOI: 10.1590/0074-02760160477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
150 Piratvisuth T, Marcellin P, Popescu M, Kapprell H, Rothe V, Lu Z. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2013;7:429-36. [DOI: 10.1007/s12072-011-9280-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
151 Suh A, Brosius J, Schmitz J, Kriegs JO. The genome of a Mesozoic paleovirus reveals the evolution of hepatitis B viruses. Nat Commun. 2013;4:1791. [PMID: 23653203 DOI: 10.1038/ncomms2798] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
152 Kang HS, Kang KS, Song BC. Precore and core promoter mutations of the hepatitis B virus gene in chronic genotype C-infected children. J Korean Med Sci. 2011;26:546-550. [PMID: 21468263 DOI: 10.3346/jkms.2011.26.4.546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
153 Miranda-Mendez A, Lugo-Baruqui A, Armendariz-Borunda J. Molecular basis and current treatment for alcoholic liver disease. Int J Environ Res Public Health. 2010;7:1872-1888. [PMID: 20622998 DOI: 10.3390/ijerph7051872] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
154 Xu T, Zhu A, Sun M, Lv J, Qian Z, Wang X, Wang T, Wang H. Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma. Oncotarget 2018;9:96-109. [PMID: 29416599 DOI: 10.18632/oncotarget.22941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
155 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
156 Yu S, Zhou Q, Zhao XM, Yuan M, Wang CT, Cheng XG, Zhang ZH, Li X. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study. Saudi J Gastroenterol. 2014;20:350-355. [PMID: 25434315 DOI: 10.4103/1319-3767.145320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
157 Wang J, Wang B, Huang S, Song Z, Wu J, Zhang E, Zhu Z, Zhu B, Yin Y, Lin Y, Xu Y, Zheng X, Lu M, Yang D. Immunosuppressive drugs modulate the replication of hepatitis B virus (HBV) in a hydrodynamic injection mouse model. PLoS One 2014;9:e85832. [PMID: 24465734 DOI: 10.1371/journal.pone.0085832] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
158 Wang ZL, Gao S, Li XY, Sun FK, Li F, Fan YC, Wang K. Demethylation of tumor necrosis factor-α converting enzyme promoter associated with high hepatitis B e antigen level in chronic hepatitis B. World J Gastroenterol 2015;21:8382-8. [PMID: 26217090 DOI: 10.3748/wjg.v21.i27.8382] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
159 Li L, Shen H, Li A, Zhang Z, Wang B, Wang J, Zheng X, Wu J, Yang D, Lu M. Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B. Virol J. 2013;10:214. [PMID: 23805945 DOI: 10.1186/1743-422x-10-214] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
160 Wang LC, Chen EQ, Cao J, Liu L, Zheng L, Li DJ, Xu L, Lei XZ, Liu C, Tang H. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients. Hepatol Int 2011;5:671-6. [PMID: 21484140 DOI: 10.1007/s12072-010-9243-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
161 Zu J, Li M, Zhuang G, Liang P, Cui F, Wang F, Zheng H, Liang X. Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model. Medicine (Baltimore) 2018;97:e0484. [PMID: 29668627 DOI: 10.1097/MD.0000000000010484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
162 Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future challenges. QJM. 2012;105:109-113. [PMID: 22252919 DOI: 10.1093/qjmed/hcr270] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
163 Li HC, Huang EY, Su PY, Wu SY, Yang CC, Lin YS, Chang WC, Shih C. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog. 2010;6:e1001162. [PMID: 21060813 DOI: 10.1371/journal.ppat.1001162] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 7.8] [Reference Citation Analysis]
164 Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011;46:1-8. [PMID: 20812021 DOI: 10.1007/s00535-010-0304-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
165 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
166 Yu W, Goddard C, Clearfield E, Mills C, Xiao T, Guo H, Morrey JD, Motter NE, Zhao K, Block TM. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem. 2011;54:5660-5670. [PMID: 21786803 DOI: 10.1021/jm200696v] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
167 Huang CJ, Wu CF, Lan CY, Sung FY, Lin CL, Liu CJ, Liu HF, Yu MW. Impact of genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression. PLoS One. 2013;8:e70169. [PMID: 23936156 DOI: 10.1371/journal.pone.0070169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
168 Soetens LC, van Benthem BH, Urbanus A, Cremer J, Benschop KS, Rietveld A, van Dijk EI, Hahné SJ. Ongoing transmission of hepatitis B virus in rural parts of the Netherlands, 2009-2013. PLoS One 2015;10:e0117703. [PMID: 25706759 DOI: 10.1371/journal.pone.0117703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
169 Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012;6:591-7. [PMID: 21769441 DOI: 10.1007/s12072-011-9299-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
170 Chen CH, Lu SN, Lee CM, Hung CH, Wang JH, Hu TH. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion. Hepatol Int 2014;8:365-74. [PMID: 26202639 DOI: 10.1007/s12072-014-9542-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
171 Liu H, Xu L, He H, Zhu Y, Liu J, Wang S, Chen L, Wu Q, Xu J, Gu J. Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein. Cancer Sci. 2012;103:2072-2081. [PMID: 22957763 DOI: 10.1111/cas.12017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
172 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
173 Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One. 2013;8:e53008. [PMID: 23326374 DOI: 10.1371/journal.pone.0053008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
174 Gao QJ, Xie JX, Wang LM, Zhou Q, Zhang SY. Interaction effects among IFN-γ+874, IL-2-330, IL-10-1082, IL-10-592 and IL-4-589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case-control study. BMJ Open 2017;7:e013279. [PMID: 28838891 DOI: 10.1136/bmjopen-2016-013279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
175 Xiao J, Lin H, Liu T, Zeng W, Li X, Shao X, Tan Q, Xu Y, Xu X, Zheng H, Ma W. Disease Burden from Hepatitis B Virus Infection in Guangdong Province, China. Int J Environ Res Public Health 2015;12:14055-67. [PMID: 26540065 DOI: 10.3390/ijerph121114055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
176 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
177 Ko YL, Sun CS, Chung KM, Lin YM, Feng IC, Sheu MJ, Koay LB, Lin CY, Ho CH, Kuo HT. Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. PLoS One. 2015;10:e0117590. [PMID: 25689069 DOI: 10.1371/journal.pone.0117590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
178 Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev 2020;159:344-63. [PMID: 32622021 DOI: 10.1016/j.addr.2020.06.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
179 Sali S, Merza MA, Saadat S, Mustafa NH, Queiky F, Yadegarynia D. Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience. Glob J Health Sci 2015;7:101-7. [PMID: 26153167 DOI: 10.5539/gjhs.v7n6p101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014;20:7207-12. [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
181 Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med 2020;14:21-9. [PMID: 31974872 DOI: 10.1007/s11684-020-0744-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
182 Zhang S, Zhao J, Zhang Z. Humoral immunity, the underestimated player in hepatitis B. Cell Mol Immunol 2018;15:645-8. [PMID: 29225341 DOI: 10.1038/cmi.2017.132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
183 Wang X, Luo J, Ma F, Kang G, Ding Z, Pan Y, Zhao Y, Chen J, Feng K, Yan L, Zhang J, Li L, Lan Q, Li D, Yang X, Li G, Yang J, Sun Q. The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study. Front Cell Infect Microbiol 2021;11:672221. [PMID: 34222044 DOI: 10.3389/fcimb.2021.672221] [Reference Citation Analysis]
184 Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol 2020;10:590-8. [PMID: 33311896 DOI: 10.1016/j.jceh.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Bertoletti A, Wang FS. Overview of the special issue on HBV immunity. Cell Mol Immunol. 2015;12:253-254. [PMID: 25864914 DOI: 10.1038/cmi.2015.24] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
186 Kramvis A, Kostaki EG, Hatzakis A, Paraskevis D. Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus. Front Microbiol. 2018;9:2521. [PMID: 30405578 DOI: 10.3389/fmicb.2018.02521] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
187 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
188 Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571. [PMID: 28122837 DOI: 10.1136/bmjopen-2016-014571] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
189 Himoto T, Masaki T. Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases. Nutrients 2020;12:E2084. [PMID: 32674425 DOI: 10.3390/nu12072084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
190 Chen HJ, Huang N, Chen LS, Chou YJ, Li CP, Wu CY, Chang YC. Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan? PLoS One 2016;11:e0161002. [PMID: 27517172 DOI: 10.1371/journal.pone.0161002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
191 Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020;55:383-9. [PMID: 32016713 DOI: 10.1007/s00535-020-01665-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
192 Zhao F, Xu G, Zhou Y, Wang L, Xie J, Ren S, Liu S, Zhu Y. MicroRNA-26b inhibits hepatitis B virus transcription and replication by targeting the host factor CHORDC1 protein. J Biol Chem. 2014;289:35029-35041. [PMID: 25342750 DOI: 10.1074/jbc.m114.589978] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
193 Jeong S, Tong Y, Sha M, Gu J, Xia Q. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:17292-300. [PMID: 28030846 DOI: 10.18632/oncotarget.14079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
194 Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-68. [PMID: 23836236 DOI: 10.1038/nm.3251] [Cited by in Crossref: 291] [Cited by in F6Publishing: 278] [Article Influence: 36.4] [Reference Citation Analysis]
195 Tsai TY, Peng CY, Yang HI, Huang YL, Tao MH, Yuan SS, Lai HC, Hsieh SL. The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection. J Biomed Sci 2018;25:59. [PMID: 30055605 DOI: 10.1186/s12929-018-0460-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
196 Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int. 2009;3 Suppl 1:24-31. [PMID: 19669243 DOI: 10.1007/s12072-009-9142-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
197 Mokhtari AM, Barouni M, Moghadami M, Hassanzadeh J, Dewey RS, Mirahmadizadeh A. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis. Hum Vaccin Immunother 2021;17:1825-33. [PMID: 33734949 DOI: 10.1080/21645515.2020.1845522] [Reference Citation Analysis]
198 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study. World J Gastroenterol. 2015;21:653-660. [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
199 Yamashita A, Fujimoto Y, Tamaki M, Setiawan A, Tanaka T, Okuyama-Dobashi K, Kasai H, Watashi K, Wakita T, Toyama M, Baba M, de Voogd NJ, Maekawa S, Enomoto N, Tanaka J, Moriishi K. Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay. Mar Drugs 2015;13:6759-73. [PMID: 26561821 DOI: 10.3390/md13116759] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
200 Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget 2017;8:51810-6. [PMID: 28881690 DOI: 10.18632/oncotarget.15395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
201 Kafeero HM, Ndagire D, Ocama P, Walusansa A, Sendagire H. Sero-prevalence of human immunodeficiency virus-hepatitis B virus (HIV-HBV) co-infection among pregnant women attending antenatal care (ANC) in sub-Saharan Africa (SSA) and the associated risk factors: a systematic review and meta-analysis.Virol J. 2020;17:170. [PMID: 33160386 DOI: 10.1186/s12985-020-01443-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol. 2014;20:7686-7695. [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
203 Shi M, Wei J, Dong J, Meng W, Ma J, Wang T, Wang N, Wang Y. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis. Mol Med Rep. 2015;11:121-126. [PMID: 25323532 DOI: 10.3892/mmr.2014.2681] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
204 Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol. 2012;86:8920-8936. [PMID: 22718830 DOI: 10.1128/jvi.00052-12] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 9.4] [Reference Citation Analysis]
205 Coppola N, De Pascalis S, Onorato L, Calò F, Sagnelli C, Sagnelli E. Hepatitis B virus and hepatitis C virus infection in healthcare workers. World J Hepatol 2016;8:273-81. [PMID: 26925201 DOI: 10.4254/wjh.v8.i5.273] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
206 Lin YC, Lee SW, Yeh HZ, Chang CS, Yang SS. The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy. Int J Clin Pharm 2018;40:169-74. [PMID: 29322472 DOI: 10.1007/s11096-017-0584-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
207 Li MR, Zheng HW, Lu JH, Ma SM, Ye LH, Liu ZQ, Zhang HC, Liu YY, Lv Y, Huang Y, Dai EH, Sun DX. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B. Oncotarget 2017;8:11063-70. [PMID: 28052021 DOI: 10.18632/oncotarget.14323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
208 Zhu X, Xie C, Li YM, Huang ZL, Zhao QY, Hu ZX, Wang PP, Gu YR, Gao ZL, Peng L. TMEM2 inhibits hepatitis B virus infection in HepG2 and HepG2.2.15 cells by activating the JAK-STAT signaling pathway. Cell Death Dis. 2016;7:e2239. [PMID: 27253403 DOI: 10.1038/cddis.2016.146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
209 Akbar SM, Al-Mahtab M, Hiasa Y. Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol 2011;46:717-23. [PMID: 21526371 DOI: 10.1007/s00535-011-0401-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
210 Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013;7:88-97. [PMID: 23518903 DOI: 10.1007/s12072-012-9343-x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
211 Mohamed R, Ng CJ, Tong WT, Abidin SZ, Wong LP, Low WY. Knowledge, attitudes and practices among people with chronic hepatitis B attending a hepatology clinic in Malaysia: a cross sectional study. BMC Public Health 2012;12:601. [PMID: 22856889 DOI: 10.1186/1471-2458-12-601] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
212 Cheng Z, Zhi X, Sun G, Guo W, Huang Y, Sun W, Tian X, Zhao F, Hu K. Sodium selenite suppresses hepatitis B virus transcription and replication in human hepatoma cell lines. J Med Virol 2016;88:653-63. [PMID: 26331371 DOI: 10.1002/jmv.24366] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
213 Viganò M, Lampertico P. Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue? Clin Liver Dis (Hoboken) 2013;2:21-3. [PMID: 30992815 DOI: 10.1002/cld.161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
214 Wang W, Dong R, Guo Y, He J, Shao C, Yi P, Yu F, Gu D, Zheng J. CircMTO1 inhibits liver fibrosis via regulation of miR-17-5p and Smad7. J Cell Mol Med 2019;23:5486-96. [PMID: 31148365 DOI: 10.1111/jcmm.14432] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
215 Zhu S, Yang YH, Gao RW, Li R, Zou YZ, Feng L, Zhang B. Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil. Drug Des Devel Ther 2018;12:41-5. [PMID: 29343941 DOI: 10.2147/DDDT.S140988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
216 Liu WC, Lin CP, Cheng CP, Ho CH, Lan KL, Cheng JH, Yen CJ, Cheng PN, Wu IC, Li IC, Chang BC, Tseng VS, Chiu YC, Chang TT. Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus. Hepatol Int 2016;10:147-57. [PMID: 26208819 DOI: 10.1007/s12072-015-9645-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
217 Sarkar N, Pal A, Das D, Saha D, Biswas A, Bandopadhayay B, Chakraborti M, Ghosh M, Chakravarty R. Virological Characteristics of Acute Hepatitis B in Eastern India: Critical Differences with Chronic Infection. PLoS One 2015;10:e0141741. [PMID: 26571502 DOI: 10.1371/journal.pone.0141741] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
218 Xie HP, Yang HZ, Wu WK, Guan WB, Ke QS, Li YW, Dai M, Xiao GM, Zhang JS, Li YM. Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase. Chin J Integr Med 2014;20:94-100. [PMID: 24619234 DOI: 10.1007/s11655-013-1569-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
219 Seth AK. HBsAg Quantification in Clinical Practice. J Clin Exp Hepatol 2012;2:75-80. [PMID: 25755408 DOI: 10.1016/S0973-6883(12)60084-X] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
220 Chan YK, Gack MU. RIG-I works double duty. Cell Host Microbe 2015;17:285-7. [PMID: 25766287 DOI: 10.1016/j.chom.2015.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
221 Su IJ, Wang LH, Hsieh WC, Wu HC, Teng CF, Tsai HW, Huang W. The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. J Biomed Sci. 2014;21:98. [PMID: 25316153 DOI: 10.1186/s12929-014-0098-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
222 Li J, Qiu X, Guo W, Yan B, Zhang S. Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. Med Oncol. 2015;32:238. [PMID: 26330362 DOI: 10.1007/s12032-015-0684-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
223 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
224 Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR. Hepatitis B vaccination. Hum Vaccin Immunother. 2015;11:53-57. [PMID: 25483515 DOI: 10.4161/hv.34306] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
225 Lee SA, Lee SY, Choi YM, Kim H, Kim BJ. Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region. World J Gastroenterol 2018;24:1084-92. [PMID: 29563753 DOI: 10.3748/wjg.v24.i10.1084] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
226 Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics 2015;5:218-26. [PMID: 25553110 DOI: 10.7150/thno.10636] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
227 Liu Y, Zhou Q, He XS, Song LM, Chen L, Jiao WJ, Shen T, Yao S, Wu H, Hu ZB, Gao TM, Li JM. Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection. Oncotarget 2016;7:4981-92. [PMID: 26701850 DOI: 10.18632/oncotarget.6650] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
228 Chin'ombe N, Chavhunduka E, Matarira HT. Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe. Infect Agent Cancer 2009;4:15. [PMID: 19814789 DOI: 10.1186/1750-9378-4-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
229 Cho YH, Jeong DW, Lee SY, Park SK, Yoon KT, Kim YJ, Lee JK, Lee YH. A Case of Wilson's Disease in Patient with Mildly Elevated Liver Enzymes. Korean J Fam Med 2011;32:205-8. [PMID: 22745856 DOI: 10.4082/kjfm.2011.32.3.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Chen Y, Huang Z, Ma D, Chen L, Lai Q, Huang X, Zhou J, Zhang X, Ma Q, Chen Z, Zuo D. Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B. BMC Immunol 2015;16:29. [PMID: 25982058 DOI: 10.1186/s12865-015-0088-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Qu LS, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One. 2014;9:e98257. [PMID: 24849936 DOI: 10.1371/journal.pone.0098257] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
232 Enderes J, Teschke J, Manekeller S, Vilz TO, Kalff JC, Glowka TR. Chronic Liver Disease Increases Mortality Following Pancreatoduodenectomy. J Clin Med 2021;10:2521. [PMID: 34200183 DOI: 10.3390/jcm10112521] [Reference Citation Analysis]
233 Wang YJ, Lu D, Xu YB, Xing WQ, Tong XK, Wang GF, Feng CL, He PL, Yang L, Tang W, Hu YH, Zuo JP. A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob Agents Chemother 2015;59:7061-72. [PMID: 26349829 DOI: 10.1128/AAC.01558-15] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
234 Hu J, Wang Y, Jiang G, Zheng J, Chen T, Chen Z, Yang M, Zhang X, Zhao H, Li L. Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infection. J Int Med Res 2020;48:300060520969582. [PMID: 33179557 DOI: 10.1177/0300060520969582] [Reference Citation Analysis]
235 Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, Wang JH, Lin ZY, Lu SN, Hu TH, Yu ML, Kao JH, Chuang WL, Chen PJ, Chen DS. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011;6:e20752. [PMID: 21695152 DOI: 10.1371/journal.pone.0020752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
236 Zeng DW, Zhang JM, Liu YR, Dong J, Jiang JJ, Zhu YY. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore). 2016;95:e2503. [PMID: 26937895 DOI: 10.1097/md.0000000000002503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
237 Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol. 2013;48:999-1005. [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
238 Yang C, Li N, Wang Y, Zhang P, Zhu Q, Li F, Han Q, Lv Y, Yu L, Wei P, Liu Z. Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res 2014;34:787-94. [PMID: 24811691 DOI: 10.1089/jir.2014.0032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
239 Melhem NM, Mahfouz RA, Kreidieh K, Abdul-Khalik R, El-Khatib R, Talhouk R, Musharrafieh U, Hamadeh G. Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon. World J Hepatol 2016;8:1212-21. [PMID: 27803766 DOI: 10.4254/wjh.v8.i29.1212] [Reference Citation Analysis]
240 Gao FY, Liu Y, Li XS, Ye XQ, Sun L, Geng MF, Wang R, Liu HM, Zhou XB, Gu LL, Liu YM, Wan G, Wang XB. Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. World J Gastroenterol. 2015;21:8373-8381. [PMID: 26217089 DOI: 10.3748/wjg.v21.i27.8373] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
241 Goyal SK, Jain AK, Dixit VK, Shukla SK, Kumar M, Ghosh J, Ranjan A, Gupta N, Tripathi M. HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. J Clin Exp Hepatol 2015;5:213-20. [PMID: 26628839 DOI: 10.1016/j.jceh.2015.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
242 Gao Y, Zhang TY, Yuan Q, Xia NS. Antibody-mediated immunotherapy against chronic hepatitis B virus infection. Hum Vaccin Immunother 2017;13:1768-73. [PMID: 28521640 DOI: 10.1080/21645515.2017.1319021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
243 Kang XZ, Guo XR, Chen BB, Zhang TY, Yuan Q, Chen PJ, Zhang J, Xia NS. The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice. Hum Vaccin Immunother 2018;14:1779-81. [PMID: 29533134 DOI: 10.1080/21645515.2018.1449553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Zhang XX, Wang LF, Jin L, Li YY, Hao SL, Shi YC, Zeng QL, Li ZW, Zhang Z, Lau GK. Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors. World J Gastroenterol. 2015;21:3554-3563. [PMID: 25834320 DOI: 10.3748/wjg.v21.i12.3554] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
245 Thibault V, Laperche S, Thiers V, Sayon S, Letort MJ, Delarocque-Astagneau E, Antona D. Molecular epidemiology and clinical characteristics of hepatitis B identified through the French mandatory notification system. PLoS One 2013;8:e75267. [PMID: 24086488 DOI: 10.1371/journal.pone.0075267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
246 Chiu YC, Lu LS, Wu KL, Tam W, Hu ML, Tai WC, Chiu KW, Chuah SK. Comparison of argon plasma coagulation in management of upper gastrointestinal angiodysplasia and gastric antral vascular ectasia hemorrhage. BMC Gastroenterol. 2012;12:67. [PMID: 22681987 DOI: 10.1186/1471-230x-12-67] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
247 Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol 2015;21:9598-606. [PMID: 26327767 DOI: 10.3748/wjg.v21.i32.9598] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
248 Meng F, Wang J, Ge J, Fan X, Wang B, Han L, Kisseleva T, Paik Y, Brenner DA, Wang K. Alteration of interferon-α/β receptors in chronic hepatitis B patients. J Clin Immunol 2011;31:521-32. [PMID: 21445562 DOI: 10.1007/s10875-011-9518-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
249 Tong Y, Liu B, Liu H, Zheng H, Gu J, Liu H, Lin M, Ding Y, Song C, Li Y. New universal primers for genotyping and resistance detection of low HBV DNA levels. Medicine (Baltimore) 2016;95:e4618. [PMID: 27537600 DOI: 10.1097/MD.0000000000004618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
250 Hsu CW, Chu YD, Lai MW, Lin CL, Liang KH, Lin YH, Yeh CT. Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression. Cancers (Basel) 2021;13:538. [PMID: 33572617 DOI: 10.3390/cancers13030538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Miyazoe Y, Miuma S, Miyaaki H, Kanda Y, Nakashiki S, Sasaki R, Haraguchi M, Shibata H, Honda T, Taura N, Nakao K. Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP-1 cells. Biomed Rep 2020;12:163-70. [PMID: 32190304 DOI: 10.3892/br.2020.1279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
252 Xu H, Zhao M, Lou G, Zheng M, Cao Q, Chen Z. New point mutations in surface and core genes of hepatitis B virus associated with acute on chronic liver failure identified by complete genomic sequencing. PLoS One 2015;10:e0123139. [PMID: 25849554 DOI: 10.1371/journal.pone.0123139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
253 Zhang H, Huo M, Chao J, Liu P. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PLoS One 2016;11:e0161936. [PMID: 27574976 DOI: 10.1371/journal.pone.0161936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
254 Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol 2014;20:7707-17. [PMID: 24976708 DOI: 10.3748/wjg.v20.i24.7707] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
255 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tuntipanichteerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study. Asian Pac J Cancer Prev 2019;20:1257-64. [PMID: 31030503 DOI: 10.31557/APJCP.2019.20.4.1257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Wang H, Chen XZ, Chen XL, Zhang WH, Liu K, Wang YJ, Tang HR, Hu JK; SIGES research group. Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES). Cancer Med 2021;10:3741-55. [PMID: 33934530 DOI: 10.1002/cam4.3901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Xiang XG, Xie Q. IL-35: a potential therapeutic target for controlling hepatitis B virus infection. J Dig Dis. 2015;16:1-6. [PMID: 25476593 DOI: 10.1111/1751-2980.12218] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
258 Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH, Wang CC, Kuo SF, Liu CH, Chen PJ. Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. Medicine (Baltimore). 2016;95:e2995. [PMID: 26962809 DOI: 10.1097/md.0000000000002995] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
259 Huang R, Yang CC, Liu Y, Xia J, Su R, Xiong YL, Wang GY, Sun ZH, Yan XM, Lu S, Wu C. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol 2015;21:9957-65. [PMID: 26379400 DOI: 10.3748/wjg.v21.i34.9957] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
260 Zhang L, Xie XY, Chen Y, Ge NL, Chen RX, Gan YH, Zhang BH, Wang YH, Ren ZG. Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads. Medicine (Baltimore) 2017;96:e9377. [PMID: 29384914 DOI: 10.1097/MD.0000000000009377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
261 Zhong HJ, Sun HH, Xue LF, McGowan EM, Chen Y. Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. World J Gastroenterol 2019;25:378-87. [PMID: 30686905 DOI: 10.3748/wjg.v25.i3.378] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
262 Li MR, Lu JH, Ye LH, Sun XL, Zheng YH, Liu ZQ, Zhang HC, Liu YY, Lv Y, Huang Y, Dai EH. Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients. Medicine (Baltimore) 2016;95:e4422. [PMID: 27559949 DOI: 10.1097/MD.0000000000004422] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
263 Yen CH, Lu YC, Li CH, Lee CM, Chen CY, Cheng MY, Huang SF, Chen KF, Cheng AL, Liao LY. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. Mol Med. 2012;18:286-296. [PMID: 22160218 DOI: 10.2119/molmed.2011.00331] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
264 Kim SE. Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B. Korean J Intern Med 2017;32:631-3. [PMID: 28704912 DOI: 10.3904/kjim.2017.209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Gu Y, Li X, Gu L, Lian Y, Wang K, Chen Y, Lai J, Mei Y, Liu J, Huang Z, Zhang M, Chen L, Huang Y. An Immuno-Clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B. Aging (Albany NY) 2020;12:26063-79. [PMID: 33401245 DOI: 10.18632/aging.202274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Liu N, Yang N, Ma W, Yang S, Hu C, Li J, Zhao Y, Xu G, He Y. Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study. Front Med (Lausanne) 2021;8:655530. [PMID: 33898489 DOI: 10.3389/fmed.2021.655530] [Reference Citation Analysis]
267 Tian X, Chong Y, Huang Y, Guo P, Li M, Zhang W, Du Z, Li X, Hao Y. Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance. Comput Math Methods Med 2019;2019:6915850. [PMID: 31281411 DOI: 10.1155/2019/6915850] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
268 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
269 Tejada-Pérez JJ, Vázquez-Vicente JJ, Herrera-Burgos MR, Martín-Martín FG, Parrón-Carreño T, Alarcón-Rodríguez R. Fendrix® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B® Vaccination. Vaccines (Basel) 2021;9:279. [PMID: 33808589 DOI: 10.3390/vaccines9030279] [Reference Citation Analysis]
270 Yang X, Li J, Liu J, Gao M, Zhou L, Lu W. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study. Medicine (Baltimore) 2017;96:e7064. [PMID: 28591041 DOI: 10.1097/MD.0000000000007064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
271 Shimizu M, Furusyo N, Ikezaki H, Ogawa E, Hayashi T, Ihara T, Harada Y, Toyoda K, Murata M, Hayashi J. Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. World J Gastroenterol 2015;21:2116-23. [PMID: 25717246 DOI: 10.3748/wjg.v21.i7.2116] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
272 Anpuanandam K, Selvarajah GT, Choy MMK, Ng SW, Kumar K, Ali RM, Rajendran SK, Ho KL, Tan WS. Molecular detection and characterisation of Domestic Cat Hepadnavirus (DCH) from blood and liver tissues of cats in Malaysia. BMC Vet Res 2021;17:9. [PMID: 33407487 DOI: 10.1186/s12917-020-02700-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Sci Rep. 2017;7:14352. [PMID: 29085039 DOI: 10.1038/s41598-017-14747-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
274 Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci 2014;11:925-35. [PMID: 25013373 DOI: 10.7150/ijms.8951] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
275 Zhong R, Tian Y, Liu L, Qiu Q, Wang Y, Rui R, Yang BF, Duan SY, Shi JX, Miao XP. HBV-related hepatocellular carcinoma susceptibility gene KIF1B is not associated with development of chronic hepatitis B. PLoS One. 2012;7:e28839. [PMID: 22363396 DOI: 10.1371/journal.pone.0028839] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
276 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol. 2010;16:3878-3887. [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
277 Dahl TF, Cowie BC, Biggs BA, Leder K, MacLachlan JH, Marshall C. Health literacy in patients with chronic hepatitis B attending a tertiary hospital in Melbourne: a questionnaire based survey. BMC Infect Dis 2014;14:537. [PMID: 25338513 DOI: 10.1186/1471-2334-14-537] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
278 Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J;  Chronic Hepatitis B Study Consortium. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65:313-320. [PMID: 25586058 DOI: 10.1136/gutjnl-2014-308546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
279 Kim SY, Kyaw YY, Cheong J. Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases. World J Gastroenterol. 2017;23:7657-7665. [PMID: 29209107 DOI: 10.3748/wjg.v23.i43.7657] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
280 Jo YJ, Kim KA, Lee JS, Kim NH, Bae WK, Song TJ, Kim JW. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir. Korean J Intern Med 2015;30:170-6. [PMID: 25750558 DOI: 10.3904/kjim.2015.30.2.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
281 Ohno M, Otsuka M, Kishikawa T, Shibata C, Yoshikawa T, Takata A, Muroyama R, Kowatari N, Sato M, Kato N, Kuroda S, Koike K. Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA. Oncotarget 2014;5:5581-90. [PMID: 25026299 DOI: 10.18632/oncotarget.2143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
282 Wu Z, Yao J, Bao H, Chen Y, Lu S, Li J, Yang L, Jiang Z, Ren J, Xu KJ, Ruan B, Yang SG, Xie TS, Li Q. The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: A 5-year follow-up study. Hum Vaccin Immunother 2018;14:1251-6. [PMID: 29337651 DOI: 10.1080/21645515.2018.1426419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Zhang Q, Liao Y, Chen J, Cai B, Su Z, Ying B, Lu X, Tao C, Wang L. Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. Sci Rep. 2015;5:17413. [PMID: 26612031 DOI: 10.1038/srep17413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
284 Guo Y, Yang Y, Bai Q, Huang Z, Wang Z, Cai D, Li S, Man X, Shi X. Cost-utility analysis of newborn hepatitis B immunization in Beijing. Hum Vaccin Immunother 2021;17:1196-204. [PMID: 33016814 DOI: 10.1080/21645515.2020.1807812] [Reference Citation Analysis]
285 Wang X, Xu ZQ, Fu JJ, Cheng LW, Li Y, Li L, Pan XC. Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon. Medicine (Baltimore). 2018;97:e10891. [PMID: 29879024 DOI: 10.1097/md.0000000000010891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
286 Montella M, D'Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, Barbieri A, D'Ursi AM, Tecce MF, Amore A, Galdiero M, Ciliberto G, Giudice A. Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Int J Endocrinol 2015;2015:854530. [PMID: 26491442 DOI: 10.1155/2015/854530] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
287 Wang H, Xiang Y, Li X, Liu S, Liu L. High lymphocyte‑to‑monocyte ratio is associated with low α‑fetoprotein expression in patients with hepatitis B virus‑associated hepatocellular carcinoma. Mol Med Rep 2020;22:2673-84. [PMID: 32945410 DOI: 10.3892/mmr.2020.11387] [Reference Citation Analysis]
288 Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727-2734. [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
289 Guo Y, Gao P, Wang H, Wu J, Bai Q, Huang L, Li S, Lv M, Shi X. Risk factors of hepatitis B virus infection between vaccinated and unvaccinated groups among spouses in 2006 and 2014: a cross-sectional study in Beijing. Hum Vaccin Immunother 2020;16:148-57. [PMID: 31287778 DOI: 10.1080/21645515.2019.1640428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
290 Li X, Gu Y, Guo X, Gu L, Zhou L, Wu X, Wang X, Stamataki Z, Huang Y. A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection. Sci Rep 2017;7:5866. [PMID: 28725030 DOI: 10.1038/s41598-017-06192-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
291 Zeng Z, Liu H, Xu H, Lu H, Yu Y, Xu X, Yu M, Zhang T, Tian X, Xi H, Guan L, Zhang J, O'Brien SJ; HBVstudy consortium. Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression. BMC Med Genomics 2021;14:84. [PMID: 33736632 DOI: 10.1186/s12920-021-00907-0] [Reference Citation Analysis]
292 Jiang DK, Ma XP, Wu X, Peng L, Yin J, Dan Y, Huang HX, Ding DL, Zhang LY, Shi Z. Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis. Sci Rep. 2015;5:16278. [PMID: 26538132 DOI: 10.1038/srep16278] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
293 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4160. [PMID: 27472685 DOI: 10.1097/MD.0000000000004160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
294 Chen EQ, Dai J, Bai L, Tang H. The efficacy of zinc finger antiviral protein against hepatitis B virus transcription and replication in tansgenic mouse model. Virol J 2015;12:25. [PMID: 25889209 DOI: 10.1186/s12985-015-0245-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
295 Burrack KS, Morrison TE. The role of myeloid cell activation and arginine metabolism in the pathogenesis of virus-induced diseases. Front Immunol 2014;5:428. [PMID: 25250029 DOI: 10.3389/fimmu.2014.00428] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
296 Gill US, Kennedy PT. New insights in the management of chronic hepatitis B. Clin Med (Lond) 2015;15:191-6. [PMID: 25824074 DOI: 10.7861/clinmedicine.15-2-191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
297 Lu Y, Wu Z, Peng Q, Ma L, Zhang X, Zhao J, Qin X, Li S. Role of IL-4 gene polymorphisms in HBV-related hepatocellular carcinoma in a Chinese population. PLoS One. 2014;9:e110061. [PMID: 25295591 DOI: 10.1371/journal.pone.0110061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
298 Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence 2017;11:85-93. [PMID: 28138226 DOI: 10.2147/PPA.S127139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
299 Ren GL, Huang GY, Zheng H, Fang Y, Ma HH, Xu MC, Zhang HB, Zhang WY, Zhao YG, Sun DY, Hu WK, Liu J. Changes in innate and permissive immune responses after hbv transgenic mouse vaccination and long-term-siRNA treatment [corrected]. PLoS One. 2013;8:e57525. [PMID: 23472088 DOI: 10.1371/journal.pone.0057525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
300 Nie H, Evans AA, London WT, Block TM, Ren XD. Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis. J Clin Virol 2011;51:234-40. [PMID: 21665530 DOI: 10.1016/j.jcv.2011.05.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
301 Ji Z, Wang T, Shao Z, Huang D, Wang A, Guo Z, Long Y, Zhang L, Su H, Zhang Q, Yan Y, Fan D. A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS One 2014;9:e97474. [PMID: 24832483 DOI: 10.1371/journal.pone.0097474] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
302 Tsai TY, Huang MT, Sung PS, Peng CY, Tao MH, Yang HI, Chang WC, Yang AS, Yu CM, Lin YP, Bau CY, Huang CJ, Pan MH, Wu CY, Hsiao CD, Yeh YH, Duan S, Paulson JC, Hsieh SL. SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection. J Clin Invest 2021;131:141965. [PMID: 34060491 DOI: 10.1172/JCI141965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Cremer J, Hofstraat SHI, van Heiningen F, Veldhuijzen IK, van Benthem BHB, Benschop KSM. Genetic variation of hepatitis B surface antigen among acute and chronic hepatitis B virus infections in The Netherlands. J Med Virol 2018;90:1576-85. [PMID: 29797607 DOI: 10.1002/jmv.25232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
304 Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8:e58071. [PMID: 23469142 DOI: 10.1371/journal.pone.0058071] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
305 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099-2108. [PMID: 25164003 DOI: 10.1002/hep.27406] [Cited by in Crossref: 592] [Cited by in F6Publishing: 517] [Article Influence: 84.6] [Reference Citation Analysis]
306 Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2014;20:6252-6261. [PMID: 24876746 DOI: 10.3748/wjg.v20.i20.6252] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
307 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
308 de Paula Machado DF, Martins T, Trevisol DJ, Vieira E Silva RA, Narciso-Schiavon JL, Schuelter Trevisol F, Schiavon Lde L. Prevalence and factors associated with hepatitis B virus infection among senior citizens in a southern brazilian city. Hepat Mon 2013;13:e7874. [PMID: 23922561 DOI: 10.5812/hepatmon.7874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
309 Huang CH, Lai YY, Kuo YJ, Yang SC, Chang YJ, Chang KK, Chen WK. Amiodarone and risk of liver cirrhosis: a nationwide, population-based study. Ther Clin Risk Manag 2019;15:103-12. [PMID: 30666120 DOI: 10.2147/TCRM.S174868] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
310 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-1651471-2334-11-165] [Reference Citation Analysis]
311 Moreno-Cubero E, Del Arco RTS, Peña-Asensio J, de Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018;24:1825-38. [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
312 Liang RL, Deng QT, Chen ZH, Xu XP, Zhou JW, Liang JY, Dong ZN, Liu TC, Wu YS. Europium (III) chelate microparticle-based lateral flow immunoassay strips for rapid and quantitative detection of antibody to hepatitis B core antigen. Sci Rep 2017;7:14093. [PMID: 29074971 DOI: 10.1038/s41598-017-14427-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
313 Hong M, Bertoletti A. Tolerance and immunity to pathogens in early life: insights from HBV infection. Semin Immunopathol. 2017;39:643-652. [PMID: 28685270 DOI: 10.1007/s00281-017-0641-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
314 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635-7643. [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
315 Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep 2017;7:1839. [PMID: 28500322 DOI: 10.1038/s41598-017-02010-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
316 Xing YF, Zhou DQ, He JS, Wei CS, Zhong WC, Han ZY, Peng DT, Shao MM, Sham TT, Mok DK, Chan CO, Tong GD. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China. PLoS One. 2018;13:e0203220. [PMID: 30180183 DOI: 10.1371/journal.pone.0203220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
317 Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Lüth S, Buchholz F, Schulze zur Wiesch J. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep. 2015;5:13734. [PMID: 26334116 DOI: 10.1038/srep13734] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 11.3] [Reference Citation Analysis]
318 Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. BMC Infect Dis. 2014;14:7. [PMID: 24397793 DOI: 10.1186/1471-2334-14-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
319 Suh A, Weber CC, Kehlmaier C, Braun EL, Green RE, Fritz U, Ray DA, Ellegren H. Early mesozoic coexistence of amniotes and hepadnaviridae. PLoS Genet 2014;10:e1004559. [PMID: 25501991 DOI: 10.1371/journal.pgen.1004559] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 7.1] [Reference Citation Analysis]
320 Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol. 2014;2:240-246. [PMID: 26355300 DOI: 10.14218/jcth.2014.00033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
321 Fang T, Long G, Wang D, Liu X, Xiao L, Mi X, Su W, Zhou L, Zhou L. A Nomogram Based on Preoperative Inflammatory Indices and ICG-R15 for Prediction of Liver Failure After Hepatectomy in HCC Patients. Front Oncol 2021;11:667496. [PMID: 34277414 DOI: 10.3389/fonc.2021.667496] [Reference Citation Analysis]
322 Kakizaki M, Yamamoto Y, Otsuka M, Kitamura K, Ito M, Kawai HD, Muramatsu M, Kagawa T, Kotani A. Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model. J Biol Chem 2020;295:12449-60. [PMID: 32651230 DOI: 10.1074/jbc.RA120.014317] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
323 Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2010;2:32ra35. [PMID: 20484730 DOI: 10.1126/scitranslmed.3001143] [Cited by in Crossref: 99] [Cited by in F6Publishing: 116] [Article Influence: 9.0] [Reference Citation Analysis]
324 Bao J, Lu Y, Deng Y, Rong C, Liu Y, Huang X, Song L, Li S, Qin X. Association between IL-18 polymorphisms, serum levels, and HBV-related hepatocellular carcinoma in a Chinese population: a retrospective case-control study. Cancer Cell Int 2015;15:72. [PMID: 26213495 DOI: 10.1186/s12935-015-0223-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
325 Cheng Z, Sun G, Guo W, Huang Y, Sun W, Zhao F, Hu K. Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines. Virol Sin 2015;30:261-8. [PMID: 26268473 DOI: 10.1007/s12250-015-3584-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
326 Inkaya AC, Demir NA, Kolgelier S, Sumer S, Demir LS, Ural O, Pehlivan FS, Aslan M, Arpaci A. Is serum high-mobility group box 1 (HMGB-1) level correlated with liver fibrosis in chronic hepatitis B? Medicine (Baltimore) 2017;96:e7547. [PMID: 28885322 DOI: 10.1097/MD.0000000000007547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
327 Hu CC, Jeng WJ, Chen YC, Fang JH, Huang CH, Teng W, Hsieh YC, Lin YC, Chien RN, Sheen IS, Lin CY. Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction. Sci Rep 2017;7:15280. [PMID: 29127350 DOI: 10.1038/s41598-017-15527-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
328 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016;8:863-73. [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
330 Kwizera R, Moibéni A, Shenawy F, Youssif M. The prevalence of hepatitis B and C among blood donors at the National Blood Transfusion Center (CNTS) in Burundi. Pan Afr Med J 2018;31:119. [PMID: 31037179 DOI: 10.11604/pamj.2018.31.119.14571] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
331 Dai T, Si J, Hao M, Li C, Liu X, Li J, Ma A. Transient Elastography with Serum Hepatitis B Surface Antigen Enhances Liver Fibrosis Detection. Med Sci Monit 2016;22:2878-85. [PMID: 27526179 DOI: 10.12659/msm.897159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
332 Allain J, Opare-sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol 2016;13:643-53. [DOI: 10.1038/nrgastro.2016.138] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
333 Chen X, Chen J, Wen J, Xu C, Zhang S, Zhou YH, Hu Y. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. PLoS One. 2013;8:e55303. [PMID: 23383145 DOI: 10.1371/journal.pone.0055303] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
334 Lu YY, Chen QL, Guan Y, Guo ZZ, Zhang H, Zhang W, Hu YY, Su SB. Study of ZHENG differentiation in hepatitis B-caused cirrhosis: a transcriptional profiling analysis. BMC Complement Altern Med 2014;14:371. [PMID: 25280538 DOI: 10.1186/1472-6882-14-371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
335 Park YM, Lee SG. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study. World J Gastroenterol 2016;22:9836-43. [PMID: 27956808 DOI: 10.3748/wjg.v22.i44.9836] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
336 Ogawa E, Yeo YH, Dang N, Le MH, Jeong D, Tran S, Henry L, Cheung R, Nguyen MH. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Netw Open 2020;3:e201844. [PMID: 32271388 DOI: 10.1001/jamanetworkopen.2020.1844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
337 Lin CL, Kao JH. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:423-431. [PMID: 28081591 DOI: 10.3350/cmh.2016.0069] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
338 Chook JB, Ngeow YF, Tee KK, Peh SC, Mohamed R. Novel Genetic Variants of Hepatitis B Virus in Fulminant Hepatitis. J Pathog 2017;2017:1231204. [PMID: 29410920 DOI: 10.1155/2017/1231204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
339 Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279. [PMID: 23390496 DOI: 10.1371/journal.pone.0054279] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
340 Zhao ZH, Fan YC, Zhao Q, Dou CY, Ji XF, Zhao J, Gao S, Li XY, Wang K. Promoter methylation status and expression of PPAR-γ gene are associated with prognosis of acute-on-chronic hepatitis B liver failure. Clin Epigenetics 2015;7:115. [PMID: 26516376 DOI: 10.1186/s13148-015-0149-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
341 Zhu M, Han M, Xiao X, Lu S, Guan Z, Song Y, Liu C. Dynamic Differences Of Red Cell Distribution Width Levels Contribute To The Differential Diagnosis Of Hepatitis B Virus-related Chronic Liver Diseases: A Case-control Study. Int J Med Sci 2019;16:720-8. [PMID: 31217740 DOI: 10.7150/ijms.31826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
342 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
343 Fan R, Lan Y, Chen J, Huang Y, Yan Q, Jiang L, Song S, Li Y. T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection. Virol J 2016;13:14. [PMID: 26809262 DOI: 10.1186/s12985-016-0473-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
344 Bertoletti A, Hong M. Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation. Front Immunol. 2014;5:441. [PMID: 25295036 DOI: 10.3389/fimmu.2014.00441] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
345 Lv J, Jin Q, Sun H, Chi X, Hu X, Yan H, Pan Y, Xiao W, Tian Z, Hou J. Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. Mediators Inflamm. 2012;2012:804043. [PMID: 23304062 DOI: 10.1155/2012/804043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
346 Lin YY, Liu C, Chien WH, Wu LL, Tao Y, Wu D, Lu X, Hsieh CH, Chen PJ, Wang HY, Kao JH, Chen DS. New insights into the evolutionary rate of hepatitis B virus at different biological scales. J Virol. 2015;89:3512-3522. [PMID: 25589664 DOI: 10.1128/jvi.03131-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
347 Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids. 2014;3:e216. [PMID: 25514649 DOI: 10.1038/mtna.2014.68] [Cited by in Crossref: 176] [Cited by in F6Publishing: 160] [Article Influence: 25.1] [Reference Citation Analysis]
348 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol. 2018;10:558-570. [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
349 Zeybel M, Vatansever S, Hardy T, Sarı AA, Cakalağaoğlu F, Avcı A, Zeybel GL, Karahüseyinoğlu S, Bashton M, Mathers JC, Ünsal B, Mann J. DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease. Clin Epigenetics 2016;8:48. [PMID: 27152124 DOI: 10.1186/s13148-016-0218-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]